| Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: a randomized, double-blind clinical trial G Farnoosh, M Akbariqomi, T Badri, M Bagheri, M Izadi, ... Archives of medical research 53 (1), 79-85, 2022 | 89 | 2022 |
| miR‐9: From function to therapeutic potential in cancer M Khafaei, E Rezaie, A Mohammadi, P Shahnazi Gerdehsang, ... Journal of Cellular Physiology 234 (9), 14651-14665, 2019 | 38 | 2019 |
| An integrated data analysis of mRNA, miRNA and signaling pathways in pancreatic cancer E Sohrabi, E Rezaie, M Heiat, Y Sefidi-Heris Biochemical Genetics 59 (5), 1326-1358, 2021 | 28 | 2021 |
| A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency E Rezaie, J Amani, AB Pour, HM Hosseini European Journal of Pharmacology 870, 172912, 2020 | 27 | 2020 |
| Bioinformatic prediction and experimental validation of a PE38-based recombinant immunotoxin targeting the Fn14 receptor in cancer cells M Keshtvarz, J Salimian, M Yaseri, SZ Bathaie, E Rezaie, A Aliramezani, ... Immunotherapy 9 (5), 387-400, 2017 | 24 | 2017 |
| The tissue expression of MCT3, MCT8, and MCT9 genes in women with breast cancer E Sohrabi, M Moslemi, E Rezaie, N Nafissi, M Khaledi, H Afkhami, J Fathi, ... Genes & Genomics 43 (9), 1065-1077, 2021 | 23 | 2021 |
| Bioinformatics predictions, expression, purification and structural analysis of the PE38KDEL-scfv immunotoxin against EPHA2 receptor E Rezaie, A Bidmeshki Pour, J Amani, H Mahmoodzadeh Hosseini International Journal of Peptide Research and Therapeutics 26, 979-996, 2020 | 20 | 2020 |
| DT389-YP7, a recombinant immunotoxin against glypican-3 that inhibits hepatocellular cancer cells: An in vitro study H Hashemi Yeganeh, M Heiat, M Kieliszek, SM Alavian, E Rezaie Toxins 13 (11), 749, 2021 | 17 | 2021 |
| Application of molecular dynamics simulations to design a dual-purpose oligopeptide linker sequence for fusion proteins E Rezaie, M Mohammadi, A Sakhteman, P Bemani, S Ahrari Journal of Molecular Modeling 24, 1-8, 2018 | 15 | 2018 |
| Different frequencies of memory B-cells induced by tetanus, botulinum, and heat-labile toxin binding domains E Rezaie, H Nekoie, A Miri, G Oulad, A Ahmadi, M Saadati, ... Microbial pathogenesis 127, 225-232, 2019 | 13 | 2019 |
| Immunotoxins immunotherapy against hepatocellular carcinoma: a promising prospect M Heiat, H Hashemi Yeganeh, SM Alavian, E Rezaie Toxins 13 (10), 719, 2021 | 10 | 2021 |
| In silico analysis of STX2a-PE15-P4A8 chimeric protein as a novel immunotoxin for cancer therapy M Keshtvarz, J Salimian, J Amani, M Douraghi, E Rezaie In Silico Pharmacology 9, 1-12, 2021 | 9 | 2021 |
| Inhibitory effect of coumarin and its analogs on insulin fibrillation/cytotoxicity is depend on oligomerization states of the protein M Akbarian, E Rezaie, F Farjadian, Z Bazyar, M Hosseini-Sarvari, EM Ara, ... Rsc Advances 10 (63), 38260-38274, 2020 | 8 | 2020 |
| Prediction of genes involved in lung cancer with a systems biology approach based on comprehensive gene information S Parvin, H Sedighian, E Sohrabi, M Mahboobi, M Rezaei, D Ghasemi, ... Biochemical Genetics, 1-21, 2022 | 7 | 2022 |
| A highly potential cleavable linker for tumor targeting antibody-chemokines M Mohammadi, E Rezaie, A Sakhteman, N Zarei Journal of Biomolecular Structure and Dynamics 40 (6), 2546-2556, 2022 | 7 | 2022 |
| Bidmeshki Pour A, Amani J, Mahmoodzadeh Hosseini H. Bioinformatics predictions, expression, purification and structural analysis of the PE38KDEL-scfv immunotoxin against EPHA2 … E Rezaie Int. J. Pept. Res. Ther 26, 979-996, 2020 | 7 | 2020 |
| Bidmeshki Pour, A.; Mahmoodzadeh Hosseini, H. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency E Rezaie, J Amani Eur. J. Pharmacol 870 (172912), 10.1016, 2020 | 7 | 2020 |
| Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity MH Ataee, SA Mirhosseini, R Mirnejad, E Rezaie, HM Hosseini, J Amani Research in Pharmaceutical Sciences 17 (4), 428-444, 2022 | 6 | 2022 |
| Engineering of cytolethal distending toxin b by its reducing immunogenicity and maintaining stability as a new drug candidate for tumor therapy; an in silico study M Keshtvarz, M Mahboobi, M Kieliszek, A Miecznikowski, H Sedighian, ... Toxins 13 (11), 785, 2021 | 6 | 2021 |
| Evaluation and comparison of immunization level between recombinant proteins of binding subunit of entrotoxigenic Escherichia coli and botulinum toxin. O GH, A MA Journal of Shahrekord University of Medical Sciences 15 (6), 2014 | 5 | 2014 |
Jafar AmaniApplied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.Verified email at bmsu.ac.ir
